AKBA

Akebia Therapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 5/10
  • Value↓ 4/10
Akebia Therapeutics sales and earnings growth
AKBA Growth
Neutral
  • Revenue Y/Y↑ 10.84%
  • EPS Y/Y↑ 63.64%
  • FCF Y/Y↑ 273.56%
Akebia Therapeutics gross and profit margin trends
AKBA Profitability
Good
  • Gross margin ↑ 81.00%
  • EPS margin↓ -8.80%
  • ROIC 5Y↓ -27.68%
Akebia Therapeutics net debt vs free cash flow
AKBA Risk
Great
  • Debt / Equity↓ 1.8
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 0.1

Akebia Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks